|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LRRFIP1 |
Gene summary for LRRFIP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LRRFIP1 | Gene ID | 9208 |
| Gene name | LRR binding FLII interacting protein 1 | |
| Gene Alias | FLAP-1 | |
| Cytomap | 2q37.3 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q32MZ4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9208 | LRRFIP1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.30e-04 | -2.53e-01 | 0.0155 |
| 9208 | LRRFIP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.14e-04 | 6.46e-01 | -0.1808 |
| 9208 | LRRFIP1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.62e-12 | 8.18e-01 | -0.0811 |
| 9208 | LRRFIP1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.06e-04 | 5.49e-01 | -0.1088 |
| 9208 | LRRFIP1 | HTA11_347_2000001011 | Human | Colorectum | AD | 8.33e-25 | 9.23e-01 | -0.1954 |
| 9208 | LRRFIP1 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.35e-10 | 1.43e+00 | -0.2602 |
| 9208 | LRRFIP1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.31e-11 | 1.04e+00 | -0.2196 |
| 9208 | LRRFIP1 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.24e-08 | 6.11e-01 | -0.1464 |
| 9208 | LRRFIP1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.85e-08 | 8.03e-01 | -0.059 |
| 9208 | LRRFIP1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 5.68e-10 | 8.79e-01 | 0.281 |
| 9208 | LRRFIP1 | F007 | Human | Colorectum | FAP | 3.41e-04 | -4.15e-01 | 0.1176 |
| 9208 | LRRFIP1 | A002-C-010 | Human | Colorectum | FAP | 1.97e-03 | -3.00e-01 | 0.242 |
| 9208 | LRRFIP1 | A001-C-207 | Human | Colorectum | FAP | 1.06e-06 | -4.02e-01 | 0.1278 |
| 9208 | LRRFIP1 | A015-C-203 | Human | Colorectum | FAP | 3.00e-31 | -4.12e-01 | -0.1294 |
| 9208 | LRRFIP1 | A015-C-204 | Human | Colorectum | FAP | 1.48e-08 | -3.65e-01 | -0.0228 |
| 9208 | LRRFIP1 | A014-C-040 | Human | Colorectum | FAP | 1.64e-05 | -3.45e-01 | -0.1184 |
| 9208 | LRRFIP1 | A002-C-201 | Human | Colorectum | FAP | 5.56e-17 | -4.15e-01 | 0.0324 |
| 9208 | LRRFIP1 | A002-C-203 | Human | Colorectum | FAP | 1.29e-03 | -2.88e-01 | 0.2786 |
| 9208 | LRRFIP1 | A001-C-119 | Human | Colorectum | FAP | 7.84e-04 | -1.48e-01 | -0.1557 |
| 9208 | LRRFIP1 | A001-C-108 | Human | Colorectum | FAP | 3.37e-16 | -2.59e-01 | -0.0272 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LRRFIP1 | SNV | Missense_Mutation | c.964N>A | p.Glu322Lys | p.E322K | Q32MZ4 | protein_coding | deleterious(0.01) | probably_damaging(0.924) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| LRRFIP1 | SNV | Missense_Mutation | c.892A>G | p.Arg298Gly | p.R298G | Q32MZ4 | protein_coding | deleterious(0) | possibly_damaging(0.812) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| LRRFIP1 | SNV | Missense_Mutation | c.731G>C | p.Arg244Thr | p.R244T | Q32MZ4 | protein_coding | deleterious(0.03) | possibly_damaging(0.809) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| LRRFIP1 | insertion | Frame_Shift_Ins | novel | c.1417dupG | p.Glu473GlyfsTer11 | p.E473Gfs*11 | Q32MZ4 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| LRRFIP1 | insertion | Frame_Shift_Ins | novel | c.1418_1419insAGCTTTCATCTTATTTCTTTTTATTTATG | p.Lys474AlafsTer31 | p.K474Afs*31 | Q32MZ4 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| LRRFIP1 | insertion | Nonsense_Mutation | novel | c.634_635insCCTGAACTGGCAGCTCTTGCCGCTGCCTTT | p.Gln212delinsProTerThrGlySerSerCysArgCysLeuTer | p.Q212delinsP*TGSSCRCL* | Q32MZ4 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
| LRRFIP1 | insertion | Frame_Shift_Ins | novel | c.1351_1352insCTGGGGAATCCAGTAG | p.Tyr451SerfsTer8 | p.Y451Sfs*8 | Q32MZ4 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
| LRRFIP1 | SNV | Missense_Mutation | novel | c.31G>A | p.Glu11Lys | p.E11K | Q32MZ4 | protein_coding | deleterious(0) | benign(0.142) | TCGA-EK-A2RE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| LRRFIP1 | SNV | Missense_Mutation | c.1574N>G | p.Ser525Cys | p.S525C | Q32MZ4 | protein_coding | deleterious(0.02) | possibly_damaging(0.764) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| LRRFIP1 | SNV | Missense_Mutation | c.645G>C | p.Glu215Asp | p.E215D | Q32MZ4 | protein_coding | tolerated(0.07) | benign(0.232) | TCGA-FU-A3HY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |